Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
UltraCision is a medical device company recognized for pioneering ultrasonic surgical technology, specifically the Harmonic Scalpel. The company's core technology utilizes ultrasonic energy to cut and seal tissue at lower temperatures than electrosurgery, minimizing lateral thermal spread and improving surgical precision. Originally an independent entity founded in 1989, UltraCision was acquired by Ethicon Endo-Surgery, a subsidiary of Johnson & Johnson, in 1995. Today, the UltraCision technology remains a cornerstone of Ethicon's surgical portfolio, widely employed in minimally invasive and open procedures across multiple surgical disciplines. The device's ability to simultaneously cut and coagulate tissue reduces the need for sutures and clips, streamlining surgical workflows. It is considered a gold standard in ultrasonic dissection for general, gynecologic, and colorectal surgeries.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on UltraCision.